DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the B-Cell Lymphomas Pipeline. Dive into DelveInsight’s comprehensive report today! @ B-Cell Lymphomas Pipeline Outlook

 

Key Takeaways from the B-Cell Lymphomas Pipeline Report

• In September 2024:- Pfizer- The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL).
• In September 2024:- Genmab- The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
• DelveInsight’s B-Cell Lymphomas pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphomas treatment.
• The leading B-Cell Lymphomas Companies such as Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
• Promising B-Cell Lymphomas Therapies such as Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.

 

Stay ahead with the most recent pipeline outlook for B-Cell Lymphomas. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ B-Cell Lymphomas Treatment Drugs

 

B-Cell Lymphoma Emerging Drugs

• Odronextamab: ZAI Lab

Odronextamab is a human IgG4-based bispecific antibody that binds to CD3, a T-cell antigen associated with the T-cell receptor complex, and CD20, a B-cell surface antigen present on normal B cells and several B cell lineage malignancies. Odronextamab is currently being studied in a potentially pivotal Phase 2 study in B-cell non-Hodgkin lymphoma (B-NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In April 2020, Zai Lab obtained exclusive rights to develop and commercialize odronextamab in greater China from Regeneron Pharmaceuticals.

• NKTR-255: Nektar Therapeutics

NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body’s innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Large B-cell Lymphoma.

• Zilovertamab Vedotin: Merck Sharp & Dohme LLC

Zilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma, or Richter transformation lymphoma. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

• Abexinostat: Xynomic Pharmaceuticals

Abexinostat (PCI-24781) is under development for the treatment of metastatic renal cell carcinoma, follicular lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, relapsed and refractory mantle cell lymphoma. It is formulated as a capsule and is administered through oral route. It acts by targeting histone deacetylase (HDAC). It was also under development for the treatment of lung cancer, colon cancer, gastric cancer, metastatic colorectal cancer, pancreatic cancer, nasopharyngeal cancer, haematological malignancies such as follicular non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL) as second line of therapy, refractory and relapsed multiple myeloma as first and second line of therapy, refractory and relapsed acute myeloid leukemia, acute lymphoblastic leukemia, high or intermediary-2 risk myelodysplastic syndrome and sarcomas as second line of therapy, fallopian tube cancer, peritoneal cancer, brain tumor and neuroblastoma. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diffuse Large B-cell Lymphoma.

 

Explore groundbreaking therapies and clinical trials in the B-Cell Lymphomas Pipeline. Access DelveInsight’s detailed report now! @ New B-Cell Lymphomas Drugs

 

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

 

B-Cell Lymphomas Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Unveil the future of B-Cell Lymphomas Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ B-Cell Lymphomas Market Drivers and Barriers

 

Scope of the B-Cell Lymphomas Pipeline Report

• Coverage- Global
• B-Cell Lymphomas Companies- Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
• B-Cell Lymphomas Therapies- Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
• B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on B-Cell Lymphomas Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ B-Cell Lymphomas Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Odronextamab: ZAI Lab
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Abexinostat: Xynomic Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TG 1801: TG Therapeutics Inc.
15. Drug profiles in the detailed report…..
16. Inactive Products
17. B-Cell Lymphoma Key Companies
18. B-Cell Lymphoma Key Products
19. B-Cell Lymphoma- Unmet Needs
20. B-Cell Lymphoma- Market Drivers and Barriers
21. B-Cell Lymphoma- Future Perspectives and Conclusion
22. B-Cell Lymphoma Analyst Views
23. B-Cell Lymphoma Key Companies
24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/